Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: IXHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incannex Healthcare Inc. filings document material-event disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company. Recent Form 8-K reports furnish Regulation FD press releases tied to clinical program updates, research partnerships, capital actions and public-company status matters.
The filing record also discloses security and governance matters, including common stock registered on The Nasdaq Stock Market LLC, emerging growth company status, a certificate amendment effecting a 1-for-30 reverse stock split, Nasdaq minimum bid price compliance and capital-structure disclosures. Other material-event filings cover agreement termination, shareholder-rights modifications and related corporate actions.
Incannex Healthcare Inc. reported receiving A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program for FY25 and expects a further approximately A$5.1 million in 2026. Combined, management highlights more than A$11.1 million in non-dilutive funding arriving in 2026.
The company notes that this cash is being received without issuing additional shares or taking on debt, supporting its debt-free balance sheet and existing cash position. Management states that the proceeds will help advance key clinical programs, including the DReAMzz study for lead candidate IHL-42X in obstructive sleep apnea, as well as IHL-675A for inflammatory conditions and PSX-001 for generalized anxiety disorder, while also supporting an active share repurchase program.
Incannex Healthcare Inc. filed a current report highlighting that Alliance Global Partners has initiated independent equity research coverage on the company. The AGP report reviews Incannex’s clinical pipeline, strategy, market opportunities and growth prospects, including lead programs IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder.
Incannex views this research coverage as an important step in expanding awareness of its clinical programs among institutional and retail investors. The company notes that analyst opinions are solely those of Alliance Global Partners, that AGP has received compensation for providing investment banking services, and includes customary forward-looking statement and risk factor cautions.
Incannex Healthcare Inc. reported no revenue and a net loss of $3.9M for the quarter and $16.8M for the nine months ended March 31, 2026. Operating expenses totaled $4.0M for the quarter, with research and development at $0.3M and general and administrative at $3.7M, the latter driven largely by higher stock-based compensation.
Cash and cash equivalents rose to $74.5M as of March 31, 2026, up from $15.0M at June 30, 2025, mainly due to equity financings including a $10.0M March 2026 registered direct offering. Stockholders’ equity increased to $75.2M. The company effected a 1-for-30 reverse stock split in February 2026.
Incannex continues to incur operating losses but believes its cash will fund operations for at least twelve months. It also has a $20M share repurchase program and has repurchased 2.1M shares to date for about $9.1M. Management discloses an ongoing material weakness in internal control over financial reporting and is implementing remediation measures.
Incannex Healthcare Inc. has officially started its DReAMzz clinical study of IHL-42X for obstructive sleep apnea. This crossover dose-optimization trial aims to refine the dosing profile and inform the design of a planned Phase III program.
The company has identified all 14 clinical sites, completed manufacturing of IHL-42X drug product, secured necessary import and export permits, and onboarded a global distribution partner to support site activation and patient dosing. DReAMzz builds on the prior Phase II RePOSA trial, where IHL-42X showed statistically significant and clinically meaningful reductions in apnea-hypopnea index, with improvements in oxygenation, sleep quality, fatigue and other patient-reported outcomes.
IHL-42X has previously received U.S. FDA Fast Track designation for obstructive sleep apnea, reflecting the seriousness of the condition and unmet medical need. DReAMzz is intended to further optimize and de-risk the Phase III pathway and forms part of Incannex’s broader strategy to develop combination therapies for chronic conditions.
Incannex Healthcare Inc. filed a Form 8-K to share that it has won the “Best New Technology Solution for Drug Development” honor in the 10th annual MedTech Breakthrough Awards. The award recognizes its lead drug candidate IHL-42X, an oral fixed-dose combination therapy being developed for obstructive sleep apnea.
In the Phase 2 RePOSA trial, IHL-42X produced statistically significant and clinically meaningful reductions in apnea-hypopnea index, with better oxygenation, sleep quality, and fatigue outcomes. Incannex highlights this recognition as supporting its strategy of developing differentiated combination medicines, including IHL-42X for sleep apnea, IHL-675A for inflammatory conditions such as rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.
Incannex Healthcare Inc. furnished a press release describing progress in its PSX-001 oral synthetic psilocybin program for Generalized Anxiety Disorder and its alignment with a new White House Executive Order on psychedelic treatments for serious mental illness.
The company reports PSX-001 showed statistically significant, clinically meaningful benefits across all primary and secondary endpoints in a completed Phase 2 trial involving 73 patients, and notes its U.S. IND is active. Incannex states it is well-funded with over $70 million in cash and no debt, and believes the Executive Order’s directives to prioritize review, enable Right to Try pathways, and initiate DEA rescheduling after successful Phase 3 may reduce regulatory and commercial risk for psilocybin-based therapies.
Incannex Healthcare Inc. has reactivated its previously approved share repurchase program and has already bought back shares over the past two trading days. The board decided to restart buybacks because it believes the company’s market value is too low relative to its cash, clinical progress, and future prospects.
Incannex reports approximately $75 million in cash on hand and no debt following recent financing, giving it flexibility to fund development of IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder while repurchasing stock. As of December 31, 2025, about $18.5 million remained available under the repurchase authorization.
The company plans to use the program opportunistically based on market conditions, trading volumes, available capital and broader needs. The buyback authorization does not require any minimum level of repurchases and may be modified, suspended or discontinued at the company’s discretion.
Incannex Healthcare Inc. filed a current report describing a new partnership with the AASM Foundation to support sleep apnea research as its lead drug IHL-42X advances. The company is joining the AASM Foundation’s Corporate Recognition Program and sponsoring a Focused Projects Grant for Junior Investigators on the diagnosis, management, and treatment of sleep apnea, to be awarded in 2026.
The filing highlights recent milestones for IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide being developed for obstructive sleep apnea, including positive Phase 2 results, FDA Fast Track designation, and progression into the DReAMzz Phase 2 crossover dose-optimisation study ahead of a planned Phase 3 program. Incannex also outlines a broader pipeline that includes IHL-675A for rheumatoid arthritis and PSX-001, a synthetic psilocybin therapy for generalized anxiety disorder.
Incannex Healthcare is highlighting a strong balance sheet following a recently completed financing. The company now holds approximately $75 million in cash with no debt, which management contrasts with a market capitalization of about $46 million, implying a negative enterprise value.
Proceeds from the financing are expected to fund the DReAMzz Phase 2 crossover dose-optimization study for lead candidate IHL-42X in obstructive sleep apnea, while preserving most existing cash for an optimized Phase 3 program. Incannex is also advancing PSX-001 for generalized anxiety disorder under an open FDA IND, and maintains a board-approved share buyback program with remaining capacity. Management views institutional participation in the financing and the company’s cash-rich, debt-free position as external validation of its clinical pipeline and strategy.
Incannex Healthcare Inc. has regained compliance with Nasdaq’s minimum bid price requirement, securing its continued listing on the Nasdaq Capital Market. Nasdaq confirmed the company met the rule after its stock closed at or above $1.00 per share for eleven consecutive business days from February 27 through March 13, 2026.
The company highlights having approximately $75 million in cash and no debt, supporting advancement of its clinical pipeline. Key programs include IHL-42X for obstructive sleep apnea, IHL-675A for inflammatory conditions such as rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.